Early Psoriatic Arthritis Often Becomes Hard to Control Before It Becomes Refractory
In a Dutch early psoriatic arthritis cohort, the newest disease-stratification frameworks quickly separated a sizeable group with persistent management difficulty from a much smaller group with truly treatment-refractory disease. Among 885 newly diagnosed, disease-modifying antirheumatic drug-naïve patients followed in the Southwest Early Psoriatic Arthritis cohort, 20% met the 2025 GRAPPA complex-to-manage definition during follow-up. The more restrictive categories were far less frequent: 4.2% fulfilled the EULAR difficult-to-manage definition, 3.8% met EULAR treatment-refractory criteria, and 1.2% met the GRAPPA treatment-refractory definition.
The gradient matters clinically. It shows that most patients do not move all the way from diagnosis to entrenched refractory disease, but a much larger slice develop a pattern of persistent burden that still demands close, individualized care.
Baseline Features Pointed to a Distinct High-Burden Phenotype
Several baseline characteristics tracked with later fulfillment of the definitions. Female sex, higher body mass index, longer symptom duration, enthesitis, and greater skin involvement were associated with meeting the criteria at baseline. Those features fit the clinical picture of more complicated psoriatic disease: enthesitis can make pain harder to localize and more resistant to routine joint-focused treatment, while heavier skin burden often signals more extensive systemic inflammatory activity. Longer untreated symptom duration may also reflect diagnostic delay, which gives inflammation more time to entrench functional impairment before disease control is established.
Sex and body composition deserve attention here. Women with psoriatic arthritis are often reported in practice to describe greater symptom burden and more difficulty reaching a stable treatment response, and higher BMI can amplify inflammatory signaling, affect mechanical load on already inflamed joints, and complicate drug pharmacokinetics. In a real-world cohort, those factors do not merely sit in the background; they shape the day-to-day course of disease.
Patient-Reported Outcomes Stayed Worse Across the More Severe Subgroups
The clearest signal came from longitudinal patient-reported outcomes. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M, and EULAR-TR consistently reported worse long-term health status than those who never met those definitions. In the mixed-effects models, the Health Assessment Questionnaire-Disability Index was higher in every one of those subgroups: β=0.17, 95% CI 0.10 to 0.24 for GRAPPA-C2M; β=0.37, 95% CI 0.22 to 0.51 for GRAPPA-TR; β=0.36, 95% CI 0.20 to 0.48 for EULAR-D2M; and β=0.40, 95% CI 0.25 to 0.55 for EULAR-TR.
Those numbers describe more than statistical separation. They point to a clinically visible gap in function that persists over time, even in a modern early-arthritis cohort where treatment decisions are being made relatively soon after diagnosis. Functional loss in psoriatic arthritis is often the product of several overlapping drivers at once: peripheral synovitis, enthesitis, axial symptoms in some patients, skin disease, pain amplification, and the downstream effects of fatigue and reduced mobility. When more than one of those processes remains active, standard escalation may still leave patients with daily disability.
GRAPPA and EULAR Definitions Captured Overlapping but Not Identical Populations
The newer GRAPPA and EULAR frameworks did not behave as interchangeable labels. GRAPPA’s C2M definition was the broadest net, identifying one-fifth of the cohort, while the D2M and TR categories from EULAR, along with the GRAPPA TR category, captured much smaller and more severe subsets. In practical terms, GRAPPA-C2M appears to identify patients earlier in the trajectory, before the disease is fully locked into treatment failure. EULAR-D2M and both TR definitions seem to isolate a smaller group with more persistent inflammatory burden and worse function.
The divergence is clinically useful. A broad definition can help clinicians recognize patients who need proactive reassessment, treatment optimization, and more careful follow-up before they drift into resistant disease. A narrower definition is better suited to identifying patients whose disease has already resisted multiple therapeutic attempts and who may need a fundamentally different management strategy.
Why the Definitions Matter at the Bedside
Psoriatic arthritis is heterogeneous by design. Some patients present with limited joint involvement and respond quickly to conventional treatment, while others carry a mixed burden of skin disease, enthesitis, obesity, longer symptom duration, and persistent disability from the outset. The pattern in this cohort suggests that the new definitions are not abstract classification exercises; they identify recognizable clinical phenotypes that are already associated with poorer functional outcomes.
That has immediate implications for rheumatology clinics. A patient with high BMI, enthesitis, longer symptom duration, and substantial skin disease should not be treated as a routine early PsA case simply because the diagnosis is new. Those features were linked to later fulfillment of the complex-to-manage and refractory definitions, and they mark a group that may require earlier multidisciplinary input, more systematic symptom review, and closer monitoring of function rather than inflammation alone.
What the Cohort Does and Does Not Prove
This was a real-world longitudinal study, which strengthens its relevance to daily practice, but the findings still reflect one cohort rather than a universal population estimate. The definitions themselves are new, and this analysis provides an early test of how they behave when applied to newly diagnosed, treatment-naïve patients over time. The key message is not that every patient with psoriatic arthritis will become difficult to treat. It is that a substantial minority already show a recognizable high-burden profile at baseline, and a smaller subset progresses into clearly refractory disease with durable disability.
For clinicians, the practical consequence is straightforward: early PsA is not always synonymous with easy-to-control disease. In this cohort, the patients who crossed into complex-to-manage or refractory territory were more often female, heavier, more skin-involved, and more likely to have enthesitis, and they carried worse function across follow-up. Those are the patients most likely to slip through the cracks if disease control is judged only by short-term symptom change rather than longitudinal disability and treatment response.